Correlation between the Warburg effect and progression of triple-negative breast cancer

被引:14
|
作者
Liu, Shaojun [1 ]
Li, Yuxuan [1 ]
Yuan, Meng [1 ]
Song, Qing [1 ]
Liu, Min [1 ]
机构
[1] Nanjing Univ Chinese Med, Dept Oncol, Suzhou TCM Hosp, Suzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 12卷
基金
中国国家自然科学基金;
关键词
Warburg effect; glycolysis; metabolic plasticity; triple-negative breast cancer; basal-like breast cancer; METABOLIC PATHWAYS; CELL COMPETITION; DRUG-RESISTANCE; TUMOR DORMANCY; METASTASIS; MECHANISMS; INHIBITION; PROMOTES; CYCLE; ACTIVATION;
D O I
10.3389/fonc.2022.1060495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted therapy due to the negative expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Although targeted therapy and immunotherapy have been shown to attenuate the aggressiveness of TNBC partially, few patients have benefited from them. The conventional treatment for TNBC remains chemotherapy. Chemoresistance, however, impedes therapeutic progress over time, and chemotherapy toxicity increases the burden of cancer on patients. Therefore, introducing more advantageous TNBC treatment options is a necessity. Metabolic reprogramming centered on glucose metabolism is considered a hallmark of tumors. It is described as tumor cells tend to convert glucose to lactate even under normoxic conditions, a phenomenon known as the Warburg effect. Similar to Darwinian evolution, its emergence is attributed to the selective pressures formed by the hypoxic microenvironment of pre-malignant lesions. Of note, the Warburg effect does not disappear with changes in the microenvironment after the formation of malignant tumor phenotypes. Instead, it forms a constitutive expression mediated by mutations or epigenetic modifications, providing a robust selective survival advantage for primary and metastatic lesions. Expanding evidence has demonstrated that the Warburg effect mediates multiple invasive behaviors in TNBC, including proliferation, metastasis, recurrence, immune escape, and multidrug resistance. Moreover, the Warburg effect-targeted therapy has been testified to be feasible in inhibiting TNBC progression. However, not all TNBCs are sensitive to glycolysis inhibitors because TNBC cells flexibly switch their metabolic patterns to cope with different survival pressures, namely metabolic plasticity. Between the Warburg effect-targeted medicines and the actual curative effect, metabolic plasticity creates a divide that must be continuously researched and bridged.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] FOSL1 transcriptionally dictates the Warburg effect and enhances chemoresistance in triple-negative breast cancer
    Zhao, Gang
    Liu, Yutong
    Yin, Shiqi
    Cao, Runxiang
    Zhao, Qian
    Fu, Yifan
    Du, Ye
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [12] Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer
    Huang, Chun
    Wang, Xuan
    Sun, Baocun
    Li, Man
    Zhao, Xiulan
    Gu, Yanjun
    Cui, Yanfen
    Li, Yan
    TARGETED ONCOLOGY, 2015, 10 (01) : 85 - 97
  • [13] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863
  • [14] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [15] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [16] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [17] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [18] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [19] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [20] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363